Sodium-glucose transporter 2 inhibitors - Pipeline Insight, 2024

Sodium-glucose transporter 2 inhibitors - Pipeline Insight, 2024

DelveInsight’s, “Sodium-glucose transporter 2 inhibitors - Pipeline Insight, 2024” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Sodium-glucose transporter 2 inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Sodium-glucose transporter 2 inhibitors Understanding

Sodium-glucose transporter 2 inhibitors: Overview

SGLT2 inhibitors, also called gliflozins, are a class of medications that alter essential physiology of the nephron; unlike SGLT1 inhibitors that modulate sodium/glucose channels in the intestinal mucosa. They act by inhibiting sodium-glucose transport protein 2 (SGLT2). SGLT2 inhibitors are used in the treatment of type II diabetes mellitus (T2DM).

Function - SGLT2 is a member of the sodium glucose cotransporter family which are sodium-dependent glucose transport proteins. SGLT2 is the major cotransporter involved in glucose reabsorption in the kidney. SGLT2 is located in the early proximal tubule, and is responsible for reabsorption of 80-90% of the glucose filtered by the kidney glomerulus. Most of the remaining glucose absorption is by sodium/glucose cotransporter 1 (SGLT1) in more distal sections of the proximal tubule.

Sodium-glucose transporter 2 inhibitors - Sodium Glucose cotransporters (SGLTs) are proteins that occur primarily in the kidneys and play an important role in maintaining glucose balance in the blood. SGLT1 and SGLT2 are the two most known SGLTs of this family. SGLT2 is the major transport protein and promotes reabsorption from the glomerular filtration glucose back into circulation and is responsible for approximately 90% of the kidney's glucose reabsorption. SGLT2 is mainly expressed in the kidneys on the epithelial cells lining the first segment of the proximal convoluted tubule. By inhibiting SGLT2, gliflozins prevent the kidneys' reuptake of glucose from the glomerular filtrate and subsequently lower the glucose level in the blood and promote the excretion of glucose in the urine.

Sodium-glucose transporter 2 inhibitors Emerging Drugs Chapters

This segment of the Sodium-glucose transporter 2 inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Sodium-glucose transporter 2 inhibitors Emerging Drugs

• Farxiga (dapagliflozin): AstraZeneca

Farxiga (dapagliflozin) is a first-in-class, oral, once-daily SGLT2 inhibitor. The research for Farxiga is advancing from cardiorenal effects to prevention and organ protection as science continues to identify the underlying links between the heart, kidneys and pancreas. Damage to one of these organs can cause the other organs to fail - contributing to leading causes of death worldwide, including T2D, HF and CKD. The drug is currently in phase 3 of development stage for the treatment of COVID 2019 infections and Heart failure.

• Henagliflozin: Jiangsu HengRui Medicine

Henagliflozin (also known as SHR3824) was developed by Jiangsu HengRui Medicine as a sodium glucose cotransporter 2 (SGLT2) inhibitor. The drug is currently in phase 3 of development stage for the treatment of Type 2 diabetes mellitus.

Further product details are provided in the report……..

Sodium-glucose transporter 2 inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Sodium-glucose transporter 2 inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players working on Sodium-glucose transporter 2 inhibitors

There are approx. 12+ key companies which are developing the Sodium-glucose transporter 2 inhibitors. The companies which have their Sodium-glucose transporter 2 inhibitors drug candidates in the most advanced stage, i.e. phase III include, AstraZeneca.

• Phases

DelveInsight’s report covers around 12+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Sodium-glucose transporter 2 inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Sodium-glucose transporter 2 inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Sodium-glucose transporter 2 inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Sodium-glucose transporter 2 inhibitors drugs.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Sodium-glucose transporter 2 inhibitors R&D. The therapies under development are focused on novel approaches for Sodium-glucose transporter 2 inhibitors.

Sodium-glucose transporter 2 inhibitors Report Insights

• Sodium-glucose transporter 2 inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Sodium-glucose transporter 2 inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Sodium-glucose transporter 2 inhibitors drugs?
• How many Sodium-glucose transporter 2 inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Sodium-glucose transporter 2 inhibitors?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Sodium-glucose transporter 2 inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Sodium-glucose transporter 2 inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• AstraZeneca
• Jiangsu HengRui Medicine
• Chong Kun Dang Pharmaceutical
• Jeil Pharmaceutical
• Sirona Biochem
• Hanmi Pharmaceutical
• Chugai Pharmaceutical
• Daewoong
• Sihuan Pharmaceutical Holdings Group
• Theracos
• HEC Pharm
• Kissei Pharmaceutical
• Novartis Pharmaceuticals
• Youngene Therapeutics
• Lyndra
• Johnson & Johnson

Key Products

• Farxiga (dapagliflozin)
• Henagliflozin
• Empagliflozin
• JP 2266
• SBM TFC 039
• HGP-1602
• Tofogliflozin
• Enavogliflozin
• Janagliflozin
• Bexagliflozin
• HEC44616
• Remogliflozin etabonate
• Licogliflozin
• YG 1699
• LYN‐045
• JNJ-28431754